The Ethical Conduct of Clinical Research Involving Children
Institute of Medicine National Academy of Sciences 2004
IOM
IOM/Academies Reports
Ethical Conduct of Clinical Research Involving Children (2004) Responsible Research (2003) Protecting Participants and Facilitating Social and Behavioral Sciences Research (2003) View or purchase at www.nap.edu
IOM
CONTEXT FOR IOM STUDY
Incentives for pediatric research 1997 FDA “pediatric exclusivity” 1998 NIH “inclusion of children” policy 2002 Best Pharmaceuticals for Children 2003 Pediatric Research Equity Act 1997 to 2001: Estimated tripling of children participating in clinical trials Underscores importance of research protections for children
IOM
CHARGE TO IOM COMMITTEE
Consider definition of minimal risk for purposes of approving research involving children Assess appropriateness of regulations for children of different ages Evaluate regulatory compliance Consider IRB roles, responsibilities
IOM
CHARGE (cont’d)
Examine comprehension of parents and children of child’s research participation Examine process for obtaining parental permission and child assent to research participation Examine appropriateness of payments to parents or children
IOM
REGULATORY FRAMEWORK
Common Rule (Subpart A): basic regulations to protect human research participants; developed by DHHS; now applies to 17 agencies Subpart D: protections for children; also adopted by Dept of Education, CIA, and SSA but not, e.g., HUD, EPA, etc. FDA: similar but separate regulations
IOM
REGULATORY FRAMEWORK
Some research that can be approved for adults cannot be approved for children If research with children involves more than minimal risk, it must (in brief summary) involve only slightly more risk AND children with disorder/condition AND vitally important have potential for direct benefit OR knowledge about the disorder/condition OR be approved by DHHS or FDA (rarely)
IOM
DEFINITION: Minimal Risk
Definition in Subpart A: probability and magnitude of harm or discomfort anticipated in research are not greater . . . than those ordinarily encountered in daily life or . . . [in] routine physical or psychological examinations or tests.
IOM
DEFINITION: Minimal Risk
Interpretation: What is minimal risk is same for healthy and ill children It is not acceptable to approve higher risk in research because children to be studied research face higher risk in their daily lives (e.g., unsafe homes) or in their medical care (e.g., painful tests or treatments)
IOM
APPROPRIATENESS OF REGULATIONS: Recommendations
All research with children should occur under umbrella of formal human research participants program that incorporates the protections of Subpart D. FDA rules should be consistent with other DHHS rules allowing waiver of parental permission when Permission not in child’s best interests Other safeguards in place
IOM
COMPLIANCE WITH REGULATIONS: Findings Lack of data—especially on research involving children—make systematic evaluation impossible. Considerable evidence of inconsistency in interpretation. Some evidence of inattention to certain aspects of regulations.
IOM
COMPLIANCE WITH REGULATIONS: Recommendations Need for more explicit federal guidance to investigators and IRBs to encourage consistency and compliance with Subpart D Guidance should be easily located on federal & IRB web sites OHRP, FDA should collect more data to guide education, QI, enforcement
IOM
COMPREHENSION OF RESEARCH: Findings Adults—as parents and in their own right—often misunderstand research Therapeutic misconception: believing purpose of clinical research is to treat rather than gain knowledge Written information is too complex Focus is too often on forms not communication
IOM
COMPREHENSION OF RESEARCH: Findings Even young children can understand basic information about what will happen in research. Older adolescents similar to adults in many aspects of understanding. Education and discussion usually increase understanding.
IOM
PERMISSION AND ASSENT: Basics Instead of informed consent— Parents provide permission and Children, when appropriate, provide their assent (or dissent)
IOM
Assent is not informed consent
Seeking assent is respectful.
My daughter will be nine years old and she needs some kind of input in what’s going on. She’s presently in a study and I need for her to be able to understand what she’s getting herself into . . . She’s at the point where she asks a lot of questions.
Andrell Vaughn, parent, 2003 IOM
PERMISSION AND ASSENT: Recommendations
Focus on process not forms
It has to be very interactive process. After I was asked this entire list of questions, I began to question my own first response. Just giving a kid a piece of paper--no matter how comprehensible--is not effective. I think the kid needs to be prompted with questions.
Sarah, research participant at age 13 IOM
PERMISSION AND ASSENT: Recommendations
Provide details in protocol on how permission and assent will be sought. Try to provide written information at 6th grade reading level. Devise ongoing process for families facing serious, acute illness.
IOM
Permission as ongoing process
There is never enough time in those situations to make an “informed decision.” We signed [the form] because that’s what you do. It’s always at the worst time to be reading this type of material . . . Parents aren’t in control nor is the child.
Joseph Lilly, parent, 2003 IOM
PAYMENTS TO PARENTS OR CHILDREN Concern: some payments may distort parent’s or child’s decisions and lead to choices that are not in the child’s best interests. Findings: limited data but evidence of considerable variability in practices Findings: lack of explicit IRB policies and guidance for investigators
IOM
PAYMENTS TO PARENTS OR CHILDREN: Recommendations IRBs should adopt explicit policies on acceptable payment practices. To equalize access to research participation, IRBs, agencies, sponsors should encourage investigators to accommodate parental work and family commitments.
IOM
PAYMENTS TO PARENTS OR CHILDREN: Recommendations Okay: reasonable reimbursement for expenses of being in research Okay: tokens of appreciation Scrutinize carefully: payments for child’s time and inconvenience for research w/o prospect of benefit Never okay: payments to parent or child for increased research risk
IOM
sammyc2007 4/12/2008 |
56 |
0 |
0 |
educational
sammyc2007 4/14/2008 |
75 |
2 |
0 |
educational
sammyc2007 4/12/2008 |
19 |
0 |
0 |
educational
sammyc2007 4/12/2008 |
19 |
0 |
0 |
educational
sammyc2007 4/11/2008 |
53 |
1 |
0 |
educational
sammyc2007 4/11/2008 |
25 |
0 |
0 |
educational
sammyc2007 3/24/2008 |
175 |
6 |
0 |
educational
sammyc2007 4/12/2008 |
26 |
0 |
0 |
educational
sammyc2007 4/11/2008 |
30 |
0 |
0 |
educational
sammyc2007 4/10/2008 |
127 |
7 |
0 |
educational
sammyc2007 4/14/2008 |
77 |
2 |
0 |
educational
sammyc2007 4/14/2008 |
69 |
2 |
0 |
educational
sammyc2007 4/14/2008 |
72 |
2 |
0 |
educational
sammyc2007 4/12/2008 |
20 |
0 |
0 |
educational
sammyc2007 6/13/2008 |
292 |
2 |
0 |
legal
sammyc2007 6/13/2008 |
249 |
0 |
0 |
legal
sammyc2007 6/13/2008 |
310 |
4 |
0 |
legal
sammyc2007 6/13/2008 |
277 |
3 |
0 |
legal
sammyc2007 6/13/2008 |
519 |
2 |
0 |
legal
sammyc2007 6/13/2008 |
422 |
1 |
0 |
legal
sammyc2007 6/13/2008 |
247 |
0 |
0 |
legal
sammyc2007 6/13/2008 |
228 |
0 |
0 |
legal
sammyc2007 6/13/2008 |
352 |
0 |
0 |
legal
sammyc2007 6/13/2008 |
315 |
0 |
0 |
legal